Extract
The main cause of death of cystic fibrosis (CF) patients is respiratory disease due to secondary infections, haemoptysis, pneumothorax, and respiratory failure [1]. In a study of 129 French CF patients who died between 2007 and 2010 without receiving lung transplantation, 8.5% of deaths were due to haemoptysis [2]. Factors associated with an increased risk of haemoptysis in CF patients include older age, advanced lung disease (forced expiratory volume in 1 s (FEV1) <70% predicted), airway colonisation by Pseudomonas aeruginosa [3], CF-related diabetes, portal hypertension, and liver cirrhosis [4]. To our knowledge, there have been no studies of the risk factors for the development of massive haemoptysis (MH) in CF patients who have previously experienced an episode of mild-to-moderate haemoptysis.
Abstract
Mild-to-moderate haemoptysis (m-mH) is common in patients with cystic fibrosis but the risk of subsequent massive haemoptysis (MH) is not known. Allergic bronchopulmonary aspergillosis and diabetes were significant predictors of MH subsequent to m-mH. https://bit.ly/30093Hw
Acknowledgements
The authors wish to thank Julien Labreuche (Univ. Lille, CHU Lille, ULR 2694 - METRICS: évaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France) for help with the statistical analysis and Anne M. O'Rourke for editing a version of the manuscript.
Footnotes
Author contributions: G. Pavaut, B. Wallaert and A. Prevotat conceived the study. G. Pavaut, A. Prevotat, B. Wallaert and M. Khyeng performed the formal analysis. B. Wallaert and A. Prevotat devised the methodology. G. Pavaut conducted the investigation. G. Pavaut, B. Wallaert and A. Prevotat wrote the original manuscript. All authors reviewed and edited the final manuscript.
Conflict of interest: G. Pavaut has nothing to disclose.
Conflict of interest: M. Kyheng has nothing to disclose.
Conflict of interest: O. Le Rouzic reports personal fees and nonfinancial support from AstraZeneca, Boehringer Ingelheim, Chiesi, Lilly and Novartis, and nonfinancial support from GlaxoSmithKline, MundiPharma, Pfizer, Teva, the Santelys Association, Vertex and Vitalaire, outside the submitted work.
Conflict of interest: T. Perez reports nonfinancial support for clinical studies in cystic fibrosis from Physioassist and Antadir outside the submitted work.
Conflict of interest: B. Wallaert reports personal fees and nonfinancial support from Roche and Boehringer Ingelheim, and nonfinancial support from Vitalaire, outside the submitted work.
Conflict of interest: A. Prevotat has nothing to disclose.
- Received March 9, 2020.
- Accepted July 19, 2020.
- Copyright ©ERS 2020
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.